TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Recommendation of "Moderate Buy" from Analysts

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the five brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $40.80.

Separately, The Goldman Sachs Group began coverage on shares of TG Therapeutics in a report on Thursday. They issued a "neutral" rating and a $37.00 target price on the stock.

TG Therapeutics Stock Performance

NASDAQ:TGTX traded down $0.07 during mid-day trading on Thursday, hitting $37.85. The stock had a trading volume of 264,926 shares, compared to its average volume of 2,885,604. The stock has a market capitalization of $6.01 billion, a price-to-earnings ratio of 158.96 and a beta of 1.91. The company has a 50 day simple moving average of $36.33 and a 200-day simple moving average of $35.21. TG Therapeutics has a 52 week low of $16.65 and a 52 week high of $46.48. The company has a current ratio of 4.02, a quick ratio of 3.04 and a debt-to-equity ratio of 1.03.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). TG Therapeutics had a return on equity of 18.88% and a net margin of 10.13%. The company had revenue of $120.86 million for the quarter, compared to the consensus estimate of $117.07 million. During the same quarter last year, the firm posted ($0.07) earnings per share. The firm's quarterly revenue was up 90.4% compared to the same quarter last year. On average, research analysts expect that TG Therapeutics will post 0.08 earnings per share for the current fiscal year.

Insider Transactions at TG Therapeutics

In other news, Director Yann Echelard sold 10,000 shares of the company's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $36.94, for a total value of $369,400.00. Following the sale, the director owned 228,816 shares of the company's stock, valued at approximately $8,452,463.04. This represents a 4.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 10.64% of the stock is owned by company insiders.

Institutional Investors Weigh In On TG Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Vermillion Wealth Management Inc. bought a new stake in TG Therapeutics during the 4th quarter worth about $30,000. NBC Securities Inc. raised its position in shares of TG Therapeutics by 82,300.0% in the 1st quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 823 shares during the period. Golden State Wealth Management LLC raised its position in shares of TG Therapeutics by 100.0% in the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 433 shares during the period. SVB Wealth LLC acquired a new stake in TG Therapeutics during the 1st quarter worth approximately $37,000. Finally, Quadrant Capital Group LLC raised its holdings in TG Therapeutics by 137.1% during the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock worth $51,000 after buying an additional 975 shares during the period. Institutional investors own 58.58% of the company's stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.